JPRN-UMIN000004266已完成2 期
A phase II feasibility trial of TS-1/PSK therapy as adjuvant chemotherapy for gastric cancer with TS-1/CDDP as neoadjuvant chemotherapy. - A phase II trial of TS-1/PSK therapy for gastric cancer with TS-1/CDDP as neoadjuvant chemotherapy.
Department of Gastroenterological Surgery Graduate School of Medicine Osaka University0 个研究点目标入组 10 人开始时间: 2010年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Double cancer. 2.Patients with administration contraindication of TS-1. 3.Patients who need continuing use of flucytosine, phenytoin, warfarin potassium. 4.Patients with severe complication (such as ileus, interstitial lung disease, lung fibrosis, diabetes that is difficult to control, heart failure, renal failure, liver failure). 5.Pregnant or lactating patients. 6.Male who have intention that get with child. 7.Patients who are not suitable for this trial by doctor's judgment.
研究者
相似试验
已完成
2 期
Phase II study of TS-1+PSK therapy as adjuvant chemotherapy during 2years against advanced gastric cancer.Advanced gastric cancerJPRN-UMIN000004419Toho University300
进行中（未招募）
1 期
Phase I/IIa Clinical Trial of KTP-001 in Subjects with Lumbar Disc HerniatioJPRN-jRCT2031210516Haro Hirotaka23
已完成
2 期
Phase II Study of TS-1 with Patient-Reported Outcome(PRO) Evaluation in Elderly Patients with Advanced NSCLCon-small cell lung cancerJPRN-UMIN000002035Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School40
已完成
不适用
Phase II trial of S-1 therapy for advanced or recurrent esophageal cancer resistant or intolerable existing treatmentsesophageal cancerJPRN-UMIN000023736Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine50
未知
2 期
Randomized phase II trial of TS-1 monotherapy versus TS-1 plus gemcitabine therapy in patients with gemcitabine-resistant advanced pancreatic cancerPatients with unresectable advanced pancreatic cancer (Stage IV, TNM Classification) who were primarily resistant to gemcitabine monotherapyJPRN-UMIN000001103Keio University School of Medicine, Department of Medicine, Division of Gastroenterology80